-+ 0.00%
-+ 0.00%
-+ 0.00%

Ascentage Pharma posts interim results presentation on 1H 2026 business update

PUBT·08/20/2026 01:16:38
Listen to the news
Ascentage Pharma posts interim results presentation on 1H 2026 business update
  • Ascentage reported 1H 2026 revenue of USD 44.5 million, up 29% year over year; product sales totaled USD 41.6 million.
  • Cash runway projected through 2027, supported by commercial sales from olverembatinib and lisaftoclax.
  • Pipeline focus centered on nine registrational trials, including four global studies; lisaftoclax and olverembatinib advanced global Phase III programs.
  • APG-3288 BTK degrader remained in Phase I dose escalation, including U.S. enrollment; APG-115 entered China’s Starlight pediatric oncology program.
  • Management added Chief Business Officer Faiçal Miyara, Chief Commercial Officer Jim Ziegler; HKEX stock short name removed the “B” marker.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascentage Pharma Group International published the original content used to generate this news brief on August 20, 2026, and is solely responsible for the information contained therein.